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Dept. of P e d i a t r i c s , St. Petersburg, FL 33731 Familial r e s i s t a n c e t o t h y r o i d hormone i s chara c t e r i z e d by e l e v a t e d t h y r o i d hormones and non-suppressed TSH i n e u t h y r o i d i n d i v i d u a l s .
We p r e s e n t a unique occurrence of an inf a n t w i t h neonatal hyperthyroidism and r e s i s t a n c e t o t h y r o i d hormone i n a family w i t h 3 g e n e r a t i o n s of r e s i s t a n c e t o t h y r o i d hormone. He was born a t 35 weeks g e s t a t i o n t o a consanguinous r e l a t i o n s h i p ( f i r s t c o u s i n s ) , b i r t h weight 1480 g, l e n g t h 46 cm. He had f e t a l and neonatal (200 beatslmin) tachycardia and exopthalmos. At 3 weeks of age t h e f o l l o w i n g was o b t a i n e d : ~4 50.7 ug/dL, T3RIA 1349 ng/dL, T3RU 45.92, r~3 618 ng/dL, TSH 389 U I U /~, f r e e T4 25.7 ng/dL, f r e e T3 5385 pg/dL, TBG 2.3 ng/dL, TBII 1 8 (n1<14), TSIg 167% (n1<130%), 4h 1231 uptake 87% and 24h 50%, moderately enlarged gland on scan, n e g a t i v e t h y r o i d a n t i b o d i e s . TRH i n c r e a s e d t h e TSH from 317 t o 413 a t 30 min. P a t i e n t ' s f a t h e r , p a t e r n a l aunt and p a t e r n a l grandmother have w e l l documented r e s i s t a n c e t o t h y r o i d hormone.
One month postpartum t h e mother had t h e following: ~4 19 ug/dL, T~R I A 298 ng/ dL, f r e e T4 4.5 n g / d~, f r e e T3 698 ~g / d~, TSH 1.0 U I U /~, TBG 2.8 ng/dL ( n l 1.6-3.6), n e g a t i v e TBII and TSIg, n l TSH response t o TRH.
Maternal g r a n d f a t h e r a l s o had e l e v a t e d t h y r o i d i n d i c e s (~4 15.2 ug/dL, T~R I A 229 ng/dL), nonsuppressed TSH 2.2 U I U /~L , and normal TRH s t i m u l a t e d TSH. We p o s t u l a t e t h a t t h i s neonate i s a homozygote f o r t h i s gene defect. We hypothesize t h a t t h i s i n f a n t ' s hyperthyroxinemia r e s u l t i n g i n t h y r o t o x i c o s i s may be expressed due t o g e n e t i c i n h e r i t e d f a c t o r s from both parents. Whether o r not G H can s t i m u l a t e growth d i r e c t l y a t t h e EP remains an important unanswered question. Several i n v e s t i g a t o r s have shown t h a t t h e l o c a l a d m i n i s t r a t i o n of GH i n t o t h e EP of hypophysectomized r a t s l e a d s t o l i n e a r growth. I f t h i s were t r u e i n primates, i t c o u l d s e r v e a s a t h e o r e t i c a l b a s i s f o r s e l e c t i v e bone remodeling. We s t u d i e d t h i s q u e s t i o n i n s i x p r e p u b e r t a l gonadectomized KM.
GROWTH HORMONE (GH) INJECTIONS
Lower l e g (LL) growth v e l o c i t y (LLG) was a s s e s s e d using a modified Valk measuring device.
Baseline LL measurements were performed weekly on both l e g s f o r 14 weeks. ' h e EP was then i d e n t i f i e d by fluoroscopy and GH was i n j e c t e d 3 times a week f o r one week i n t o one l e g while s a l i n e was i n j e c t e d i n t o t h e o t h e r .
GH was given i n a dose of .4 and .8 u n i t s per i n j e c t i o n .
Each RM served a s h i s own c o n t r o l . lhe i n v e s t i g a t o r s were blinded t o t h e i n j e c t i o n schedule. Testosterone e n a n t h a t e , a s a s i n g l e intramuscular dose of 2 mg/kg, was given t o 3 R M a s a p o s i t i v e c o n t r o l f o r LLG. The r e s u l t s of t h e s e s t u d i e s , expresed a s percent growth change over b a s e l i n e , a r e p r e s e n t e d below TOTAL DOSE EXPERIMENTAL GROUP CONTROL GROUP GH 1.2 U 66% 187% GH 2.4 U 59% 166% T 2mg/kg 285% 85% It i s c l e a r from t h e s e d a t a t h a t i n our primate model GH administered d i r e c t l y i n t o t h e EP f a i l e d t o a c c e l e r a t e LLG. 460 Ben R. Manilac, 11. Shohat and Alan 11. Klein, UCLA School of Eledicine, Cedars-Sinai I.!edical Center, Dept. of P e d i a t r i c s , Los Angeles. We r e p o r t a 34 week female i n f a n t , b i r t h weight=3.7 Kg, length=49.5 cni with macroglossia, n~icrocep!laly, d i a s t a s i s r e c t i , pnln~onic s t e n o s i s , visceron~ej:aly, abnormal e a r c r e a s e and m u l t i p l e o t h e r problen~s i n c l u d i n g increased d i r e c t b i l i r u b i n and l i v e r f u n c t i o n t e s t s . Severe hypoglycemia developed when weaned from p o r e n t e r a l n u t r i t i o n a t 6 weeks of ageeInitia1. s t u d i e s r e v e a l e d growth hormone (GII)=7.7 ng/ml, c o r t i s o l (C)=9.7 mcg/ml, i n s u l i n (1)=2.1 mcU/n~l when hlood glucose (X)= 21 ng/tll. Euglycca~ia was maintained by continuous g a s t r i c fecdinp. 6.6
The reason f o r t h e !hypo:;lyce~nia i s u n c l e a r . Ilypcrinsulinemia o r ahnormal ICF I and I1 wer? not denionstrated. GI1 therapy was unsuccessful.Factors o t h e r than i n s u l i n , growth hor~none and t h e known IGF's appear t o play an important p a r t i n . t h e lnacrosomia and hypog1yccn1i.a seen i n t h i s i n f a n t . While 3 patients with panhyl)opitoitarisn~ had low LH (X = 3 mIU/n11) and low T (z = 11 ng/dl), one had a high FSH (52 n~IU/ml). Two patielits with Prader Willi had nornral gonadotrophins and high T (509, 610 ng/dl). Two patients with mixed gonadal dysgenesis (SO/XY) and 3 patients with SY goni~dal dysecne!sis with &llerian remnants had normal to high-normal LH (?, = 19 mIUin11) ~n d 1ow~-normal T (S = 158 : 32 ng/dl): FSH was high-norn~al t o high (X = 15 mIC!ntl). Values in a patient with "vanishing testes" were FSH 212 sIU/n~l. LH 167 mIU/ml. and T <30 &dl.
A patient with Leydig cell hypoplasia had low T (22 ng/dl), normal FSH (2.9 nlIL'/n11), but low LII (3 nlIU:n~l). Tlco patients with high gonadotrophins and normal testosterone and dihydrotestosterone a r e awaiting t e s t s of androgen receptor function. In G patients who were judged idiopathic. no helpful gonadotrophin pattern was found. Two patients are s t i l l bejng evaluated. In co~iclusion, we found windoru period LH, FSH, and testosterone values useEu1 and generally consistent with results obtai~ied by other diagnostic tests. and I n t e r n a l Medicine, ~h a r l o t t e s ; i l l e~, VA.
Nocturnal G H s e c r e t o r y p a t t e r n s i n response t o GHRH (1 uglkgl3h SC) were s t u d i e d i n 6 GHRH-deficient c h i l d r e n . Four r e c e i v e d GHRH therapy f o r a t l e a s t 6 mo and were s t u d i e d repeatedly.
Two received GHRH every 3h f o r 24h b e f o r e and then d u r i n g t e s t i n g .
During 19 s t u d y p e r i o d s G H r o s e s i g n i f i c a n t l y i n response t o 66 of 7 2 GHRH doses (92%) a s determined by a r e g i o n a l t h r e s h o l d p u l s e a n a l y s i s program. The a m p l i t u d e v a r i e d w i t h t i m e i n a l l s u b j e c t s d u r i n g t h e s t u d y p e r i o d s without r e l a t i o n s h i p t o d u r a t i o n of therapy.
I n t h e f o u r with m u l t i p l e s t u d i e s one G H p u l s e predominated and occurred a t a c o n s t a n t t i m e of day i n e a c h i n d i v i d u a l .
Peak GH l e v e l s (nglml) f o r one p a t i e n t a r e shown (times a r e of GHRH doses). 9.5 6.7 13.8 20.9 7 5.7 2.9 3.1 11.6 9 4.4 6.2 2.8 20.8 The t i m e of g r e a t e s t response was 0500h i n t h r e e of t h e f o u r .
No c h i l d had a pretreatment dominant p u l s e a t t h e same t i m e a s t h e one during GHRH therapy.
The p e r s i s t e n t v a r i a b i l i t y i n G H response t o m u l t i p l e equal GHRH doses s u g g e s t s a SS s e c r e t o r y rhythm.
The temporal c o n s i s t e n c y of maximal G H r e l e a s e t o GHRH might r e f l e c t t h a t i n d i v i d u a l ' s n a d i r of n o c t u r n a l SS s e c r e t i o n .
These d a t a s u g g e s t t h a t t r e a t m e n t of some GHRH d e f i c i e n t c h i l d r e n w i t h a s u s t a i n e d r e l e a s e form of GHRH w i l l r e s u l t i n p u l s a t i l e G H s e c r e t i o n .
TREATMENT WITB ATENOLOL INCREASES TEE GROUTE EOBnONE (GH) RESPONSE TO EXOGENOUS GH RELEASING B O W O N E (GERH) BUT FAILS TO AUQlENT ENDOGENOUS GH SECRETION
463 IN NON-GB DEFICIENT SHORT BOYS. Paul Martha Jr.. ms and I n t e r n a l Medicine, C h a r l o t t e s v i l l e . V A S e l e c t i v e beta-adrenergic blockade (BAB) w i t h a t e n o l o i (A) i n c r e a s e s t h e GH response t o i v GHRH i n normal men a s p r e v i o u s l y r e p o r t e d from t h i s l a b o r a t o r y . This s t u d y was designed t o determine (1) i f A would enhance G H r e l e a s e i n GHRH-deficient p a t i e n t s r e c e i v i n g GHRH therapy and (2) i f A would i n c r e a s e G H s e c r e t i o n i n boys w i t h c o n s t i t u t i o n a l d e l a y of growth (CDG).
Two c h i l d r e n w i t h i d i o p a t h i c GHRH d e f i c i e n c y were s t u d i e d from 2000 t o O8OOh p r i o r t o and while r e c e i v i n g l o n g term GHRH subcutaneously every 3h.
Blood was withdrawn e v e r y 20 min f o r G H determination.
This t e s t was r e p e a t e d on t h e following day both b e f o r e and while r e c e i v i n g GHRH except A, 25 mg, was given o r a l l y a t 1030 and 1600h. G H s e c r e t i o n was i n c r e a s e d by A before (1948 t o 3124 and 718 t o 1157 ng/ml min) a n d d u r i n g ( 1 4 6 0 t o 3628 a n d 1363 t o 6386 ng/ml min) GHRH therapy. S i x h e a l t h y boys ages 7 t o 15 y with CDG had BAB w i t h A.
Each had a s i g n i f i c a n t i n c r e a s e i n t h e peak G H r e l e a s e t o GHRH ( 5 5 . 2 L 1 3 . 5 v s 8 7 . 7 2 1 9 . 0 ng/ml,p<O.Ol) and i n t h e a r e a u n d e r t h e GH vs time curve (3916 + 701 v s 5624 + 986 n g / d min,p<O.Ol) following A. However, BZ w i t h A f a i l e d t o enhance t h e endogenous (12h n o c t u r n a l ) G H s e c r e t i o n (5597 + 637 v s 4168 L 475 ng/ml min, p=0.125) suggesting t h a t A m a y n o t be a p p r o p r i a t e t o promote growth i n boys w i t h CDG i n c o n t r a s t t o t h o s e w i t h GHRH d e f i c i e n c y .
